202 related articles for article (PubMed ID: 23948956)
21. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
23. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.
Breuer RH; Snijders PJ; Smit EF; Sutedja TG; Sewalt RG; Otte AP; van Kemenade FJ; Postmus PE; Meijer CJ; Raaphorst FM
Neoplasia; 2004; 6(6):736-43. PubMed ID: 15720799
[TBL] [Abstract][Full Text] [Related]
25. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
26. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.
Caganova M; Carrisi C; Varano G; Mainoldi F; Zanardi F; Germain PL; George L; Alberghini F; Ferrarini L; Talukder AK; Ponzoni M; Testa G; Nojima T; Doglioni C; Kitamura D; Toellner KM; Su IH; Casola S
J Clin Invest; 2013 Dec; 123(12):5009-22. PubMed ID: 24200695
[TBL] [Abstract][Full Text] [Related]
27. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
28. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens.
Steele JC; Torr EE; Noakes KL; Kalk E; Moss PA; Reynolds GM; Hubscher SG; van Lohuizen M; Adams DH; Young LS
Br J Cancer; 2006 Nov; 95(9):1202-11. PubMed ID: 17024127
[TBL] [Abstract][Full Text] [Related]
29. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
Balasubramanian S; Adhikary G; Eckert RL
Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
[TBL] [Abstract][Full Text] [Related]
30. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
[TBL] [Abstract][Full Text] [Related]
31. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
32. Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas.
Raaphorst FM; Vermeer M; Fieret E; Blokzijl T; Dukers D; Sewalt RG; Otte AP; Willemze R; Meijer CJ
Am J Pathol; 2004 Feb; 164(2):533-42. PubMed ID: 14742259
[TBL] [Abstract][Full Text] [Related]
33. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
34. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
[TBL] [Abstract][Full Text] [Related]
35. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.
Saieg MA; Geddie WR; Boerner SL; Bailey D; Crump M; da Cunha Santos G
Cancer Cytopathol; 2013 Jul; 121(7):377-86. PubMed ID: 23361872
[TBL] [Abstract][Full Text] [Related]
36. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
Karanikolas BD; Figueiredo ML; Wu L
Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877
[TBL] [Abstract][Full Text] [Related]
37. Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation.
Raaphorst FM; Otte AP; van Kemenade FJ; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Meijer CJ
J Immunol; 2001 May; 166(10):5925-34. PubMed ID: 11342607
[TBL] [Abstract][Full Text] [Related]
38. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
[TBL] [Abstract][Full Text] [Related]
39. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.
Hernández-Muñoz I; Taghavi P; Kuijl C; Neefjes J; van Lohuizen M
Mol Cell Biol; 2005 Dec; 25(24):11047-58. PubMed ID: 16314526
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]